Skip to main content
. 2023 Jul 27;18:e46. doi: 10.15420/ecr.2023.04

Table 2: Quality of Life and Symptoms Over Long-term Follow-up in the EARLY-AF Trial[7].

Year 1, Mean ± SD Year 2, Mean ± SD Year 3, Mean ± SD
AFEQT score
Mean difference*		 8.0 ± 2.2
ABL 26.9 ± 1.9 versus AAD 22.9 ± 2.0		 9.0 ± 2.3
ABL 29.7 ± 2.0 versus AAD 24.7 ± 2.0		 7.4 ± 2.2
ABL 28.1 ± 2.0 vs AAD 24.8 ± 2.0
EQ-5D score
Mean difference† 		0.05 ± 0.02
ABL 0.06 ± 0.01 versus AAD 0.01 ± 0.01		 0.03 ± 0.02
ABL 0.06 ± 0.02 versus AAD 0.04 ± 0.02		 0.0 5 ± 0.02
ABL 0.06 ± 0.02 vs AAD 0.01 ± 0.02
AF symptoms
RR		 RR 0.56, 95% CI [0.35–0.88]
ABL 14.9% versus AAD 26.8%		 RR 0.34, 95% CI [0.15–0.75]
ABL 5.5% versus AAD 16.0%		 RR 0.28, 95% CI [0.13–0.61]
ABL 4.8% versus AAD 17.1%

*Clinically meaningful difference = 5 points; †clinically meaningful difference = 0.03. AAD = antiarrhythmic drugs; ABL = ablation; AFEQT = AF Effect on QualiTy-of-life.